- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00139750
12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking Cessation
June 1, 2007 updated by: Pfizer
A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of CP-526,555 In Smokers Motivated To Stop Smoking
The purpose of the study is to examine the safety and efficacy and dose-response relationship of three doses of CP-526,555 for 12 weeks compared with placebo for smoking cessation; including post-treatment follow-up of smoking status to one year from randomization.
A small satellite protocol (A3051048) investigated safety of a second course of therapy in subjects who did not quit.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
600
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Fukuoka, Japan
- Pfizer Investigational Site
-
Ohita, Japan
- Pfizer Investigational Site
-
-
Chiba
-
Noda, Chiba, Japan
- Pfizer Investigational Site
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan
- Pfizer Investigational Site
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan
- Pfizer Investigational Site
-
-
Oita-ken
-
Beppu-shi, Oita-ken, Japan
- Pfizer Investigational Site
-
-
Osaka
-
Toyonaka, Osaka, Japan
- Pfizer Investigational Site
-
-
Saga
-
Tosu, Saga, Japan
- Pfizer Investigational Site
-
-
Shizuoka
-
Hamamatsu, Shizuoka, Japan
- Pfizer Investigational Site
-
-
Tokyo
-
Edogawa-ku, Tokyo, Japan
- Pfizer Investigational Site
-
Minato-ku, Tokyo, Japan
- Pfizer Investigational Site
-
Musashino, Tokyo, Japan
- Pfizer Investigational Site
-
Setagaya-ku, Tokyo, Japan
- Pfizer Investigational Site
-
Shinagawa-ku, Tokyo, Japan
- Pfizer Investigational Site
-
Toshima-ku, Tokyo, Japan
- Pfizer Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Cigarette smokers who are motivated to stop smoking and have smoked an average of at least 10 cigarettes per day
Exclusion Criteria:
- Subjects who have used a nicotine replacement product within 30 days of the study screening visit or intend to use it during the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
4-week continuous quit rate (CQR) for Weeks 9-12
|
Secondary Outcome Measures
Outcome Measure |
|---|
|
Continuous abstinence for Weeks 9-52 and Weeks 9-24
|
|
Long-term quit rate at Week 52
|
|
4-week CQR for Weeks 4-7
|
|
7-day point prevalence of asbtinence Weeks 12, Week 24, and Week 52
|
|
Continuous abstinence from TQD (Week 1) through Week 12
|
|
Weekly average number of cigarettes smoked per day for Weeks 1-12
|
|
Evaluation of withdrawal symptoms by the Minnesota Nicotine Withdrawal Scale
|
|
Evaluation of smoking satisfaction by the Smoking Effects Inventory
|
|
Evaluation of urge to smoke by the Brief Questionnaire of Smoking Urges
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Nakamura M, Oshima A, Ohkura M, Arteaga C, Suwa K. Predictors of lapse and relapse to smoking in successful quitters in a varenicline post hoc analysis in Japanese smokers. Clin Ther. 2014 Jun 1;36(6):918-27. doi: 10.1016/j.clinthera.2014.03.013. Epub 2014 May 5.
- Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther. 2007 Jun;29(6):1040-56. doi: 10.1016/j.clinthera.2007.06.012.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2004
Study Completion (Actual)
February 1, 2006
Study Registration Dates
First Submitted
August 29, 2005
First Submitted That Met QC Criteria
August 30, 2005
First Posted (Estimate)
August 31, 2005
Study Record Updates
Last Update Posted (Estimate)
June 4, 2007
Last Update Submitted That Met QC Criteria
June 1, 2007
Last Verified
June 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A3051046
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.